INVO - Mergers and acquisitions

SARASOTA, Fla., Nov. 8, 2021 /PRNewswire/ -- INVO Bioscience, Inc. ("INVO" or the "Company") (NASDAQ:INVO), a medical device company focused on commercializing the world's only in vivo culture system (IVC), today announced it will regain full U.S. commercialization rights for its patented INVOcell® device due to Ferring International Center S.A.'s termination for convenience of that certain Distribution Agreement dated November 12, 2018 with INVO, which termination will officially take effect on January 31, 2022. Over the past three years, INVO has been executing on a multi-faceted commercialization strategy which includes partnering to open dedicated "INVO Centers" focused on INVOcell and t

SARASOTA, Fla., Sept. 9, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:INVO), a medical device company focused on commercializing the world's only in vivo culture system (IVC), INVOcell®, an affordable and effective infertility treatment, announced today that it has completed the acquisition of a Canadian-based entity that was originally formed to offer INVOcell in Canada. The entity had previously completed a number of important procedures and documentation necessary to establish INVOcell within clinical operations in Canada. INVO Bioscience anticipates leveraging this entity to advance the distribution of INVOcell, and take advantage of the existing product registration which approved